PATENT CLAIM ANALYSIS

Application Number: 15917504
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["435", "372000"]

Abstract:
Methods and compositions for differentiating pluripotent stem cells into cells of endothelial and hematopoietic lineages are disclosed.

Claim (Index 16):
A method of treating a blood disorder in a subject, the method comprising administering therapeutic cells comprising CD43 +  hematopoietic progenitors composed of CD43 + CD235a + CD41a +  erythromegakaryocytic progenitors and lin\u2212CD34 + CD43 + CD45 \u2212/\u2212  multipotent hematopoietic progenitors to treat the blood disorder, the therapeutic cells made by the method comprising the steps of:\n (a) exposing human pluripotent stem cells to a xenogen-free and serum albumin-free mixture comprising components of about 25 ng/ml to about 50 ng/ml FGF2, at least 50 ng/ml to about 250 mg/ml of bone morphogenetic protein 4 (BMP4), Activin A of less than 15 ng/ml, and about 1 mM to about 2 mM LiCl under hypoxic conditions for a period of about two days to form a population of therapeutic  EMH lin \u2212 KDR + APLNR + PDGFRalpha +  primitive mesoderm cells with mesenchymoangioblast potential without the formation of embryoid bodies or coculture with stromal cell lines; \n (b) exposing cells at the primitive mesoderm stage of step (a) to a mixture comprising components FGF2 and VEGF under hypoxic conditions for a period of about 1-2 days to obtain a population comprising  EMH lin\u2212KDR + APLNR \u2212 PDGFRalpha +  primitive mesoderm with hemangioblast (HB-CFC) potential and hematovascular mesoderm cells ( EMH lin \u2212 KDR hi APLNR + PDGFRalpha lo/\u2212 ) enriched in cells with a potential to form hematoendothelial clusters when cultured on OP9 cells; \n (c) exposing the cells at the hematovascular mesoderm stage of step (b) to a mixture comprising components FGF2, VEGF, IL6, SCF, TPO, and IL3 for about one day to achieve formation of CD144 + CD73 + CD235a/CD43 \u2212  non-hemogenic endothelial progenitors (non-HEP), CD144 + CD73 \u2212 CD235a/CD43 \u2212  hemogenic endothelial progenitors (HEPs), CD144 + CD73 \u2212 CD235a/CD43 + 41a \u2212  angiogenic hematopoietic progenitors (AHP), and CD43 + CD41a +  hematopoietic progenitor cells; \n (d) exposing the HEPs and emerging hematopoietic progenitor cells to a mixture comprising components FGF2, VEGF, IL6, SCF, TPO, IL3 under normoxia for about three days resulting in hematopoietic expansion to obtain a population of CD43 +  hematopoietic progenitors composed of CD43 + CD235a + CD41a +  erythromegakaryocytic progenitors and lin\u2212CD34 + CD43 + CD45 +/\u2212  multipotent hematopoietic progenitors; wherein the population of CD43 +  hematopoietic progenitors comprise the therapeutic cells.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 90.0
- Lexical Diversity: 1.125
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14206778', '14955760', '11520871', '13194623', '14359517']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6559034802639124
- 35 USC 102 Novelty (BERT): 0.7660033162480464
- Combined Prediction Score: 0.6669134638623259
- Mean Citation Score: 640.185966
- Max Citation Score: 1108.4266
- Similarity Product: 897.1418173917293

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test